On the other hand, significant decreases of the obesity parameters were observed in the OB/OR group in comparison to the OB group, showing that orlistat is a potent gastro-pancreatic lipase drug that is capable of reducing the body weight after six weeks of the therapeutic period. This evidence concerns the gene PNLIP and Obesity.